Rakovina has been invited to present at the 6th biennial Canadian Cancer Research Conference which is being held virtually Nov. 8-11, 2021.

Presentation highlights pre-clinical data from Rakovina Therapeutics’ novel kt-3000 series dual PARP-HDAC inhibitors..

Apabetalone is the only drug of its class with a well-established safety record in human clinical trials, with well over 4200 patient-years

The granted patent claims cover the composition of matter and uses of drug candidates from Rakovina Therapeutics’ kt-2000 series...

Successful Completion and Promising Results of Investigator-led APPROACH-p Trial Sets the Stage for a Larger Multicenter Trial

Velada brand cannabis products both online and in store in the province of ON starting January 2022

The conference has attracted academics, scientists, and pharmaceutical industry representatives from across the globe.....

TGSC has also initiated a podcast marketing campaign with AdvertiseCast to continue expanding their e-commerce presence throughout NA..

Resverlogix and EVERSANA Announce Partnership to Support the Pending Launch of the Initial Commercialization of Apabetalone for COVID-19...